Considering their mutually compensatory and sometimes antagonistic effects, a less potent and well-balanced agonist that targets all three PPAR subtypes may provide more comprehensive protection from metabolic dysfunction and accompanied cardiovascular disease, as well as offset of undesired side effect such as weight gain and bone fracture associated with highly active PPARγ agonists in T2DM patients [9, 10]. Here, PPARG is linked to type 2 diabetes mellitus.